Argenica Therapeutics (ASX:AGN) has strengthened the evidence base behind its lead neuroprotective candidate, ARG-007, with new independently generated data confirming a potent therapeutic effect in a validated preclinical model of acute ischaemic stroke. …
Argenica validates optimal dose of ARG-007 in independent preclinical stroke study
November 25, 2025 Australian Biotech
Latest Video
New Stories
-
Argenica validates optimal dose of ARG-007 in independent preclinical stroke study
November 25, 2025 - - Australian Biotech -
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - - Latest News -
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 - - Australian Biotech -
New review recommends a balanced and measured approach to adopting AI in clinical practice
November 24, 2025 - - BioPharma -
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - - Latest News -
Moderna names CSIRO scientist Dr Anne Klein as 2025 Australian Fellow
November 24, 2025 - - Australian Biotech -
New national report warns of deepening ovarian cancer burden and calls for urgent action
November 24, 2025 - - Latest News